Formulary Search Results for: ABIRATERONE ACETATE
8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocol for the indications as outlined below.
Metastatic castration resistant prostate cancer (mCRPC):
- Use in adult men in whom chemotherapy is not yet clinically indicated after failure of androgen deprivation therapy according to regional protocol
- Use in adult men who have received only one prior chemotherapy regimen. Click here for regional protocol [NHS network access required]
- With prednisone or prednisolone for the treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy. Click here for regional protocol [NHS network access required]
Non-metastatic prostate cancer:
- Use of abiraterone acetate plus prednisolone in combination with androgen deprivation therapy for the treatment of high-risk hormone-sensitive non-metastatic prostate cancer (off label indication)
Metastatic prostate cancer:
- Abiraterone acetate plus prednisolone in combination with androgen deprivation therapy for the treatment for newly diagnosed low-risk metastatic hormone-sensitive prostate cancer patients who are not suitable for currently accessible on-label alternatives (off label indication).
11.4.1 Eye-corticosteroids - View Category
9.5.2.2 Phosphate-binding agents - View Category
7.3.2.2 Parenteral progestogen-only contraceptives - View Category
4.8.1 Control of the epilepsies - View Category
Restrictions:
Restricted to initiation by specialists in epilepsy.
Prescribing Notes:
Use as monotherapy in the treatment of partial-onset seizures, with or without generalisation, in adults with newly diagnosed epilepsy is not recommended for use in NHSScotland by the SMC and is non-Formulary.
13.6.1 Topical preparations for acne - View Category
3.4.3 Allergic emergencies - View Category
Restrictions:
It is restricted to specialist use only on the advice of the Immunology Service.
7.2.3 Preparations for uterine fibroids - View Category
Restrictions:
The treatment of moderate to severe symptoms of uterine fibroids in adult women is restricted to the following MHRA advice:
- intermittent treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age who are not eligible for surgery or where surgery has failed
- treatment is to be initiated and supervised by a physician experienced in the diagnosis and treatment of uterine fibroids
Please refer to MHRA information prior to initiation.
7.3.5 Emergency contraception - View Category
Prescribing Notes:
- Ulipristal is licensed for use in women presenting up to 120 hours after unprotected intercourse for whom the insertion of an IUD is not acceptable.
- Please follow the FSRH guidance for appropriate use.
8.2.4 Other immunomodulating drugs - View Category
Restrictions:
Restricted to specialist use only. Restricted to use under the provision of the ‘Risk Sharing Scheme’ between the Scottish Executive Health Department and the manufacturers (NHS HDL (2002)6).